



Rolf Stahel

Kontakt

Rolf Stahel

Publikationen (11)

Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau J, Jean D, Felley-Bosco E. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. *JTO Clin Res Rep* 2022; 3:100430.

Gachechiladze M, Soltermann A, Rulle U, Weder W, Stahel R, Kolář Z, Shani I, Hajduch M, Vbrková J, Vojta P, Smičková P, Kolek V, Überall I, Skanderová D, Škarda J, Jörger M. Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma. *Lung Cancer* 2020; 147:30-38.

Kresoja-Rakic J, Cerciello F, Früh M, Stahel R, Weder W, Lam W, Martinez V, Minatel B, Ronner M, Kirschner M, Szpechcinski A, Felley-Bosco E. miR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and Surgery. *Noncoding RNA* 2019; 5

Wolpert F, Preusser M, Kaufmann P, Reynolds N, Roth P, Frauenfelder T, Dummer R, Stahel R, Stupp R, Neidert M, Regli L, Andratschke N, Leske H, Petyt G, Füreder L, Rushing E, Berghoff A, Weller M, Le Rhun E. Diagnostic value of F-fluorodesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. *Eur J Cancer* 2018; 96:64-72.

Gachechiladze M, Soltermann A, Weder W, Stahel R, Baty F, Kolář Z, Bouchal J, Langová K, Grygárová I, Kolek V, Škarda J, Jörger M. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients. *Lung Cancer* 2017; 105:31-38.

Samaras P, Renner C, Stahel R, Knuth A, Taverna C, Schäfer N, Mischo A, Schanz U, Siciliano R, Honegger H, Haile S, Buset E, Petrusch U, Zardavas D, Stenner-Liewen F. Prognostic factors for survival in lymphoma patients after autologous stem cell transplantation. *Swiss Med Wkly* 2013; 143:w13791.

Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. *Lung Cancer* 2012; 79:59-64.

Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. *J Clin Oncol* 2010; 28:4480-4.

Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23:705-11.

Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2003; 21:1752-9.

D'Addario G, Ketterer N, Fey M, Cavalli F, Lohri A, Egli F, Stahel R, Maibach R, Torhorst J, Dieterle A, Cerny T. HIV-testing and newly-diagnosed malignant lymphomas. The SAKK 96/90 registration study. Leukemia & lymphoma 2003; 44:133-8.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch